Epizyme to Participate in Jefferies Virtual London Healthcare Conference
Epizyme, a commercial-stage biopharmaceutical company (Nasdaq: EPZM), announced that CEO Robert Bazemore will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 12:35 p.m. ET. A live webcast will be available on the company's investor website, archived for 60 days.
Epizyme focuses on developing novel epigenetic therapies, with TAZVERIK® approved for specific cancer types. The company aims to match innovative treatments with genetic drivers of diseases, enhancing patient care.
- None.
- None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in a fireside chat during the Jefferies Virtual London Healthcare Conference on Thursday, Nov. 18, 2020 at 12:35 p.m. ET.
A live webcast of the fireside chat will be available in the investor section of the company’s website and will be archived for 60 days following the presentation.
About Epizyme, Inc.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). The company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them. For more information, visit www.epizyme.com.
TAZVERIK® is a registered trademark of Epizyme, Inc. For full prescribing information, please visit TAZVERIK.com.
